@article{RudovickBraunerEnglertetal.2018, author = {Rudovick, Ladius and Brauner, Jan M. and Englert, Johanna and Seemann, Carolina and Plugaru, Karina and Kidenya, Benson R. and Kalluvya, Samuel E. and Scheller, Carsten and Kasang, Christa}, title = {Prevalence of pretreatment HIV drug resistance in Mwanza, Tanzania}, series = {Journal of Antimicrobial Chemotherapy}, volume = {73}, journal = {Journal of Antimicrobial Chemotherapy}, number = {12}, doi = {10.1093/jac/dky332}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227124}, pages = {3476-3481}, year = {2018}, abstract = {Background: In a 2008-10 study, we found a pretreatment HIV drug resistance (PDR) prevalence of 18.2\% in patients at Bugando Medical Centre (BMC) in Mwanza, Tanzania. Objectives: To determine the prevalence of PDR and transmitted HIV drug resistance (TDR) in patients visiting the BMC from 2013 to 2015. Methods: Adult outpatients were sequentially enrolled into two groups, separated by whether they were initiating ART. Previous exposure to antiretroviral drugs, except for prevention of mother-to-child transmission, was an exclusion criterion. HIV pol sequences were analysed according to WHO guidelines for surveillance of PDR and TDR. Results: Two hundred and thirty-five sequences were analysed (138 ART initiators, 97 non-initiators). The prevalence of PDR was 4.7\% (95\% CI 2.6\%-8.2\%) overall, 3.1\% (95\% CI 1.1\%-8.7\%) for non-initiators and 5.8\% (95\% CI 3.0\%-11.0\%) for ART initiators. PDR to NNRTIs and nucleoside or nucelotide reverse transcriptase inhibitors was found in 3.0\% (95\% CI 1.5\%-6.0\%) and 1.7\% (95\% CI 0.7\%-4.3\%) of patients, respectively. Resistance to PIs was not observed. The prevalence of TDR was 6.0\% (95\% CI 3.6\%-9.8\%). Conclusions: Prevalence of PDR significantly decreased compared with 2008-10 and was below the WHO-defined threshold for triggering a public health response. National and systematic surveillance is needed to inform Tanzania's public health strategy.}, language = {en} }